Calamos Advisors
STIM icon

Calamos Advisors’s Neuronetics STIM Stock Holding History

Calamos Advisors’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-363,468
Closed -$5.82M – 1044
2021
Q2 		$5.82M Sell
363,468
-16,150
-4% -$223K 0.03% 527
2021
Q1 		$4.7M Buy
379,618
+208,985
+122% +$3.2M 0.03% 549
2020
Q4 		$1.9M Buy
+170,633
New +$1.28M 0.01% 640

Other funds holding STIM

CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Calamos Advisors's STIM Position: Q3 2021 in Review

Calamos Advisors sold out of Neuronetics (STIM) in Q3 2021, closing a stake of 363,468 shares — an estimated $5.82M sold.

Calamos Advisors first reported a position in STIM in Q4 2020 and held it in 3 quarters. The position peaked at $5.82M in Q2 2021. 97 funds tracked by Wall St. Rank hold STIM as of Q3 2021.

  • Calamos Advisors reported no remaining Neuronetics position as of Q3 2021 after selling out during the quarter.
  • Calamos Advisors sold 363,468 Neuronetics shares in Q3 2021, an estimated $5.82M.
  • Calamos Advisors first reported a position in Neuronetics in Q4 2020 and held it in 3 quarters.
  • Calamos Advisors's Neuronetics position peaked at $5.82M in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Neuronetics as of Q3 2021.

Based on Calamos Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.